British American Tobacco edges past forecasts as smokeless growth gathers pace

British American Tobacco reported 2025 adjusted operating profit up 2.3% to £11.57bn (vs. £11.45bn expected) and adjusted diluted EPS of 352p (consensus 340p), with reported revenue down 1.0% but up 2.1% at constant currency. Growth was driven by combustibles and Velo nicotine pouches as 'new categories' revenue rose 7% and contribution jumped 77.1% to £442m (smokeless consumers +4.7m to 34.1m; smokeless now 18.2% of group revenue). Management boosted shareholder returns—dividend +2% to 245.04p and a £1.3bn buyback (up from £1.1bn)—while flagging a more cautious 2026 outlook with revenue guidance of 3–5% and adjusted EPS growth of 5–8%, expected toward the lower end of ranges.

Analysis

Market structure: BTI's increased £1.3bn buyback and 2% dividend lift reinforce cash-return signalling while new categories (smokeless revenue £442m, 18.2% of group) are scaling — smokeless added 4.7m consumers to 34.1m, returning to double-digit H2 growth. Expect incumbents with large retail footprints (BTI, PM) to benefit as pricing power on combustibles persists; smaller challenger brands face distribution constraints. Currency (reported revenue -1% vs +2.1% CER) means sterling moves remain an earnings swing factor for next 4 quarters.

Risk assessment: Key tail risks are regulatory shocks (US state/FDA restrictions on nicotine pouches or EU excise increases >5%), accelerated plain-packaging or litigation outcomes, and US concentration risk given Velo reliance; any of these could compress EPS by >10% within 12 months. In the near term (days–weeks) stock reaction will be driven by buyback framing and guidance nuance; medium/long term (quarters) execution on smokeless margin mix and global excise trends matter. Hidden dependency: Velo's US roll-out cadence and FDA/retailer acceptance underpin the 5–8% EPS guidance.

Trade implications: Favours structurally long BTI with position sizing tied to regulatory read; credit spread tailwinds modestly improve BTI bond technicals, but FX hedges advisable if sterling moves >3% vs USD. Use options to cap downside: sell covered calls on existing exposure or buy 12-month call spreads to express 15–30% upside while limiting premium; avoid high-gamma short-dated straddles given policy risk.

Contrarian angle: Market may underprice sustainable share gains in smokeless — 18.2% revenue share implies faster margin mix shift than consensus assumes; conversely guidance at lower end of ranges is conservative and could be a buy signal if FY26 EPS growth re-accelerates. Watch cross-company outcomes — if BTI converts more combustibles consumers to pouches, pricing elasticity eases, enabling >8% EPS upside over 12–24 months, a scenario consensus is likely underweight.

Key Decisions for Investors

• Establish a 2–3% long position in British American Tobacco (BTI) within portfolios over 3–12 months, target 20% total return and sell-to-stop at 12% loss; thesis: £1.3bn buyback + 18.2% revenue from smokeless should drive EPS upside if Velo roll-out continues.
• Implement a directional options trade: buy a 12-month BTI call spread sized to express 15–30% upside (e.g., long Jan-2027 call, short a higher strike) to limit premium outlay while capturing secular smokeless adoption; size 0.5–1% notional of portfolio.
• Construct a pair trade: long BTI 2% vs short Philip Morris (PM) 1.5% over 9–12 months, target relative outperformance of 8–12%; stop if BTI underperforms PM by >7% or if regulatory risk materializes (see next item).
• Monitor regulatory catalysts closely for the next 30–90 days: FDA statements on nicotine pouches, EU/UK excise proposals and major US state bans. If a credible restriction or excise increase (>5% revenue impact estimate) is announced, reduce gross BTI exposure by 50% within 5 trading days.